RespireRx Pharmaceuticals — 2017 Marcum Microcap Conference
37 slides from RespireRx Pharmaceuticals's conference presentation, Jun 16, 2017
Slide 1: RespireRx Pharmaceuticals - 2017 Marcum Microcap Conference
DR) RespireRx Pharmaceuticals Inc James S. Manuso, Ph.D., President & CEO 2017 Marcum Microcap Conferen\ New York, June 16, 201: Medicines for Respiratory Diseases
Slide 2: Forward Looking Statements
Forward Looking Statements BR The matters discussed in this presentation that are not historical facts are "forward- looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and we intend that such forward-looking stat
Slide 3: Breath
Breath "Breath is the universal factor of life. We are born the first time we inspire, and we die the last time we expire. Breath is life itself. In Sanskrit the same word means both breath and life." uses Abbot George Burke
Slide 4: Innovative Medicines for Respiratory Diseases
Innovative Medicines for Respiratory Diseases (A)RespireRx Cannabinoids — Dronabinol - Phase 3 ready for Obstructive Sleep Apnea (OSA) Ampakines — CX1739 & CX717 — 3 successful Phase 2A trials demonstrating target engagement and proof of concept for opioid induced respiratory depression (RD) and cen
Slide 5: Sleep Apnea: A National Health Epidemic
Sleep Apnea A National Health Epidemic
Slide 6: Sleep Apnea: A National Health Epidemic
Sleep Apnea: A National Health Epidemic (FQ RespireRx Pharmaceuticals inc Over 35 Million Americans Stop Breathing Every Night From 5 — 50 Times Per Hour This Is Not Merely Snoring
Slide 7: Sleep Apnea and its Measurement
Sleep Apnea and its Measurement (ARespireRx + Apnea - Cessation of breathing for > 10 seconds + Hypopnea - Abnormal severe slowing of breathing for > 10 seconds + Apnea - Hypopnea Index (AHI) — An indicator of the severity of sleep apnea. AHI is the average number of apnea- hypopnea events per hour
Slide 8: Three Types of Sleep Apnea
Three Types of Sleep Apnea (A)RespireRx * Obstructive (OSA) - a peripheral phenomenon that occurs when throat muscles intermittently relax and block airway during sleep. OSA may be accompanied by snoring * Central (CSA) - a brain-mediated phenomenon that occurs when breathing control centers in the
Slide 9: Company Focus: Apneas
Company Focus: Apneas (QRespireRx * Dronabinol for Obstructive Sleep Apnea * Ampakines to address: Post-surgical Central Sleep Apnea Chronic CSA Spinal Cord Injury Related Apnea
Slide 10: Respiratory Diseases Product Pipeline
Respiratory Diseases Product Pipeline a RespireRx Compound | Indication Preclinical Phase 1 Phase 2 ee _——— Dronabinol Apnea Chronic CSA, ox1739 Post-surgical CSA Opioid-induced RD ox7i7 ‘Spinal Cord Injury ox1942 Drug-induced RD ——7 (injectable) 10
Slide 11: Dronabinol: Breakthrough Treatment for Obstructive Sleep Apnea
Dronabinol: Breakthrough Treatment for Obstructive Sleep Apnea as Pharmaceuticals inc 1
Slide 12: Obstructive Sleep Apnea: Epidemiology
Obstructive Sleep Apnea: Epidemiology (A)RespireRx 12% Prevalence OSA (AHI>5) 294M, 80% 20% Undiagnosed Diagnosed 25M 5.9m —— a vordeedBresthogin Aus” American Academy of Sleep Medicine 2016 2
Slide 13: OSA - Costs of the Problem in the US
OSA - Costs of the Problem in the US (aR)RespireRx Pharmaceuticals Ine Estimated Annual Indicated us Annual Cost to Drug Therapy Disease State Prevalence USEconomy Expenditures. osats 29.4 Million $162.0 Billion $o Asthma®7 16.4 Million $18.3 Billion $13.5 Billion Hypertension®° 43.2 Million $73.4 B
Slide 14: Dronabinol: A Breath Treatment for OSA
Dronabinol: A Brea h Treatment for OSA (>)RespireRx + Dronabinol is 4-THC + Oral, small molecule + Cannabinoid receptor agonist + Reduces apnea by acting on spinal ganglia controlling muscle tone in throat + Positive Phase 2A and 2B clinical trials in OSA Dronabinol Background + FDA approved for the
Slide 15: No Approved Medicines Exist for OSA
Res| No Approved Medicines Exist for OSA oN) Current Approved Treatments CPAP device Surgery Dental devices Exercises Stimulants for next day sleepiness SERN CPAP is the Standard Treatment for OSA » 30% of patients prescribed CPAP never initiate treatment * Over 50% of patients stop using CPAP in th
Slide 16: Successful Phase 2B PACE Trial in OSA
Successful Phase 2B PACE Trial in OSA )RespireRx - Six week, double-blind, placebo controlled clinical study in patients with OSA - Doses: Placebo, 2.5 mg and 10 mg at night + Conducted by University of Illinois at Chicago and Northwestern University - Fully funded by NIH - >$5 million 16
Slide 17: Successful Phase 2B PACE Trial in OSA
Successful Phase 2B PACE Trial in OSA )RespireRx - 56 evaluable patients completed study = Placebo, n= 17 = 2.5 mg dronabinol, n = 19 = 10 mg dronabinol, n = 20 - Results revealed a statistically significant improvement in Primary Outcome Measures: = Apnea-Hypopnea Index (AHI) (2.5 and 10 mg)! = ESS
Slide 18: PACE Phase 2B Clinical Trial Results
PACE Phase 2B Clinical Tri ResHlreRK OSA After 6 Weeks of Dronabinol Treatment Pel fee p= 001 Apnea-Hypopnia Index (AHI)
Slide 19: PACE Phase 2B Trial Compared to Phase 2A
PACE Phase 2B Trial Compared to Phase 2A ®)RespireRx + pe.02, compared placebo for Phase 2A 0 Pe » 2% 20 s Phase 2A* 0 5 PACE Phase 28 Apnea-Hypopnia Index (AHI) Placebo 25mg 10mg * Double blind, placebo controlled dase ascending study in patients with OSA, n=19 19
Slide 20: Dronabinol - Phase 3 Regulatory Strategy
Dronabinol — Phase 3 Regulatory Strategy )RespireRx + Meet with FDA during H1/2017 - Finalize the Phase 3 trial plan required for approval - Agree on a Special Protocol Assessment (“SPA”) - Position dronabinol as a breakthrough medicine - Seek fast track designation - Facilitate and hasten the devel
Slide 21: Protecting Dronabinol in the Market
Protecting Dronabinol in the Market (a )RespireRx Method-of-Use patents for dronabinol in OSA Hatch-Waxman protection — 3 years Schedule III drug: off-label use monitored by US government, discouraging generic manufacturers from selling off-label Off-label use of generics and medical marijuana are n
Slide 22: The Dronabinol Opportunity
The Dronabinol Opportunity (AYRespireRx Commercial Potential First medicine available for OSA Ease of Use/Better Patient Compliance Low cost Safe and effective Potential for better cardiovascular ‘outcomes Changes the nature of OSA treatment Broadly expands prescriber base from sleep specialists to
Slide 23: Ampakines for Opioid Induced Apneas
Ampakines for Opioid Induced Apneas 23
Slide 24: Chronic Opioid Use and Central Sleep Apnea
hronic Opioid Use and Central Sleep Apnea (Gd Respirerx Pharmaceuticals Ine + Opioid Epidemic = U.S. pharmacies annually dispense 245 million Rx for opioid pain relievers + 10-11 million patients in the US on chronic opioid therapy for pain + Opioid induced respiratory depression is manifested as CS
Slide 25: Post-Surgical Central Sleep Apnea: Outcomes
Pos' urgical Central Sleep Apnea: Outcomes ®)RespireRx Pharmaceuticals Inc __ tenet of Stay (days) Mortality Rate (%) Hospital Costs ($ billions) wat Respiratory without Respiratory se | Go Depression Depression warn Respiatoy Without Depron” Respiratory + 4-8% of in-patient surgical patients in U.S
Slide 26: Ampakines for CSA
Ampakines for CSA (ARespireRx Current CSA Treatments + No medicine or device is approved for CSA + CPAP is contra-indicated Ampakines for CSA + Post-surgical CSA produced by opioid pain management Short term use (<1 week) + CSAcaused by opioid use in patients with chronic pain Chronic use - longer t
Slide 27: Translational Approach to Respiratory Disorders
anslational Approach to Respiratory Disorders ()RespireRx Dereca (ne) « Brain stem nuclei that regulate breathing contain opiate and AMPA _ glutamate receptors that inhibit and excite cell activity, respectively = Ampakines act as_ positive, allosteric modulators of the AMPA-type glutamate receptor
Slide 28: Development Status of the Ampakines
Development Status ofthe Ampakines (JACI + CX1739 = Successfully completed four Phase 1 Safety Trials = Successfully completed Phase 2A Trial in opioid-induced respiratory depression * CX717 = Successfully completed multiple Phase 1 Safety Trials = Successfully completed two Phase 2A Trials in opioi
Slide 29: Ampakines Reduce Opioid Induced Respiratory Depression in Phase 2A Clinical Trials
Ampakines Reduce Opioid Induced Respiratory R ireR Depression in Phase 2A Clinical Trials mespireh me < Se cat Placebo cxn7 Placebo X1739 a3 1500 me 300 me ae Z ze ee. ge a B88 +0 ge ES oo cer 2 os <0 geo £% 30 BE as ZA qa Ampakines reduce opioid induced respiratory depression without altering analg
Slide 30: Ampakine Indications and IP
Ampakine Indications and IP CG QRespireRx * Targeted Indications = Post-surgical, opioid-induced CSA = Chronic CSA = Spinal cord injury = Combination formulation with an opioid for treatment of chronic pain + Intellectual Property Protection (owned and licensed) = Issued Composition-of-Matter Patent
Slide 31: Summary
Summary es Pharmaceuticals inc 31
Slide 32: Respiratory Diseases Product Pipeline
Respiratory Diseases Product Pipeline a RespireRx Compound | Indication Preclinical Phase 1 Phase 2 ee _——— Dronabinol Apnea Ccontral Seep Apnea oxt739 Post-surgicl Apnea Opioid-induced RD oxn7 Spinal Cord Injury ox1942 Drug-induced RD ——7 (injectable) 32
Slide 33: Development Milestones
Development Milestones (A)RespireRx Pharmaceuticals ine 302017 402017 102018 202018 += 3q2018 402018 Dronabinol FDA Regulatory - Prepare and submit IND Pivotal Clinical Trial Proprietary Extended Release Formulation Development cx1739 FDA Regulatory - Prepare and submit IND Central Sleep Apnea Cinic
Slide 34: Capital Structure and Market Metrics
Capital Structure and Market Metrics /gitgulas Pro Forma at March 31, 2017 ‘Common Stock (including 140,000 shares issued in March 2017 2,289,000 Common Stock Equivalents of Convertible Notes 31,000 ‘Common Stock Equivalents of all Options and Warrants Granted (includes 140,000 warrants issued March
Slide 35: Management and Directors
James Manuso Amold Lippa Jeff Margolis Richard Purcell Katie MacFarlane James Sapirstein John Greer agement an Directo GS RespireRx President, CEO & Vice Chairman CSO & Executive Chairman CFO, VP, Secretary/Treasurer, Director Senior VP, R& D Director Senior VP, Napo Pharmaceuticals Director CEO, Co
Slide 36: Innovative Medicines for Respiratory Diseases
Innovative Medicines for Respiratory Diseases (A)RespireRx Cannabinoids — Dronabinol - Phase 3 ready for Obstructive Sleep Apnea (OSA) Ampakines — CX1739 & CX717 — 3 successful Phase 2A trials demonstrating target engagement and proof of concept for opioid induced respiratory depression (RD) Medicin
Slide 37: RespireRx Pharmaceuticals - 2017 Marcum Microcap Conference
DR) RespireRx Pharmaceuticals Inc James S. Manuso, Ph.D., President & CEO 2017 Marcum Microcap Conferen\ New York, June 16, 201: Medicines for Respiratory Diseases
RespireRx Pharmaceuticals — 2017 Marcum Microcap Conference on 6ix